Mateusz Adam Krzyscik
Overview
Explore the profile of Mateusz Adam Krzyscik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pozniak M, Sokolowska-Wedzina A, Jastrzebski K, Szymczyk J, Porebska N, Krzyscik M, et al.
Mol Oncol
. 2020 Jun;
14(9):1998-2021.
PMID: 32511887
Fibroblast growth factor receptor 1 (FGFR1) transmits signals through the plasma membrane regulating essential cellular processes like division, motility, metabolism, and death. Overexpression of FGFR1 is observed in numerous tumors...
12.
Krzyscik M, Zakrzewska M, Otlewski J
Mol Pharm
. 2020 Jun;
17(7):2734-2748.
PMID: 32501706
In spite of significant progress in the field of targeted anticancer therapy, the FDA has approved only five ADC-based drugs. Hence the search for new targeted anticancer agents is an...
13.
Krzyscik M, Opalinski L, Otlewski J
Mol Pharm
. 2019 Jun;
16(8):3588-3599.
PMID: 31244217
Targeted therapies are rapidly evolving modalities of cancer treatment. The largest group of currently developed biopharmaceuticals is antibody-drug conjugates (ADCs). Here, we developed a new modular strategy for the generation...
14.
Krzyscik M, Zakrzewska M, Sorensen V, Sokolowska-Wedzina A, Lobocki M, Weronika Swiderska K, et al.
ACS Omega
. 2018 Jul;
2(7):3792-3805.
PMID: 30023704
Antibody-drug conjugates (ADCs) are a new class of anticancer therapeutics that combine the selectivity of targeted treatment, ensured by monoclonal antibodies, with the potency of the cytotoxic agent. Here, we...
15.
Balek L, Buchtova M, Bosakova M, Varecha M, Foldynova-Trantirkova S, Gudernova I, et al.
Biomaterials
. 2018 Jun;
176:106-121.
PMID: 29879652
The blocking of specific protein-protein interactions using nanoparticles is an emerging alternative to small molecule-based therapeutic interventions. However, the nanoparticles designed as "artificial proteins" generally require modification of their surface...
16.
Kmiecik S, Krzyscik M, Filip-Psurska B, Wietrzyk J, Boratynski J, Goszczynski T
Postepy Hig Med Dosw (Online)
. 2017 Aug;
71(0):618-623.
PMID: 28791956
Introduction: The use of hybrid molecules has become one of the most significant approaches in new cytotoxic drug design. This study describes synthesis and characterization of conjugates consisting of two...